Connor, Clark & Lunn Investment Management Ltd. Adma Biologics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 588,874 shares of ADMA stock, worth $10.9 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

588,874

Previous 791,791 25.63%

Holding current value

$10.9 Million

Previous $8.85 Million 32.98%

% of portfolio

0.06%

Previous 0.04%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$11.21 - $20.03 $2.27 Million - $4.06 Million	-202,917 Reduced 25.63%	588,874 $11.8 Million
Q2 2024 Aug 09, 2024	BUY	$5.98 - $11.18 $2.79 Million - $5.22 Million	466,551 Added 143.45%	791,791 $8.85 Million
Q1 2024 May 09, 2024	SELL	$4.4 - $6.74 $306,539 - $469,562	-69,668 Reduced 17.64%	325,240 $2.15 Million
Q4 2023 Feb 09, 2024	SELL	$3.08 - $4.52 $499,745 - $733,392	-162,255 Reduced 29.12%	394,908 $1.78 Million
Q3 2023 Nov 13, 2023	SELL	$3.47 - $4.61 $928,179 - $1.23 Million	-267,487 Reduced 32.44%	557,163 $1.99 Million
Q2 2023 Aug 10, 2023	BUY	$3.12 - $4.22 $20,173 - $27,286	6,466 Added 0.79%	824,650 $3.04 Million
Q1 2023 May 09, 2023	BUY	$3.01 - $3.87 $10,077 - $12,956	3,348 Added 0.41%	818,184 $2.71 Million
Q4 2022 Feb 10, 2023	BUY	$2.47 - $3.88 $1.6 Million - $2.52 Million	649,198 Added 391.94%	814,836 $3.16 Million
Q3 2022 Nov 10, 2022	BUY	$2.03 - $2.86 $272,397 - $383,771	134,186 Added 426.64%	165,638 $403,000
Q2 2022 Aug 05, 2022	BUY	$1.43 - $2.2 $44,976 - $69,194	31,452 New	31,452 $62,000

Others Institutions Holding ADMA

# of Institutions

318

Shares Held

184M

Call Options Held

917K

Put Options Held

91.6K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.62B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Adma Biologics, Inc. Transaction History